<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347618</url>
  </required_header>
  <id_info>
    <org_study_id>UGUP14107</org_study_id>
    <nct_id>NCT02347618</nct_id>
  </id_info>
  <brief_title>Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer</brief_title>
  <official_title>Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a short-course of stereotactic body&#xD;
      radiotherapy (SBRT) prior to surgical resection of pancreatic adenocarcinoma is feasible and&#xD;
      well-tolerated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 2, single center, prospective, single arm feasibility study of the use&#xD;
      of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically&#xD;
      resectable pancreatic adenocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 2 or greater toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Number of incidence of grade 2 or greater toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with no further growth of cancer at original site (Local control)</measure>
    <time_frame>2 years</time_frame>
    <description>Count subjects with no further growth of cancer at original site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count subjects with Recurrence of cancer in other body sites</measure>
    <time_frame>2 years</time_frame>
    <description>Compare recurrence locations of treated patients relative to historical controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression of pancreatic cancer</measure>
    <time_frame>4 years</time_frame>
    <description>Duration of progression free survival of treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>4 years</time_frame>
    <description>Measure duration of survival of treated patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Preoperative SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative SBRT</intervention_name>
    <description>This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.</description>
    <arm_group_label>Preoperative SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with pathologically proven diagnosis of adenocarcinoma of the head of the&#xD;
             pancreas&#xD;
&#xD;
          2. CT w/ contrast using the pancreas protocol or MRI of the abdomen with contrast within&#xD;
             6 weeks prior to registration&#xD;
&#xD;
          3. CT chest or PET/CT within 6 weeks prior to registration&#xD;
&#xD;
          4. Clinically determined to be resectable based on NCCN Criteria:&#xD;
&#xD;
          5. No radiographic evidence of superior mesenteric vein or portal vein distortion&#xD;
&#xD;
          6. No evidence of distant metastasis&#xD;
&#xD;
          7. Clear fat planes around the celiac axis, hepatic artery, and superior mesenteric&#xD;
             artery&#xD;
&#xD;
          8. No enlarged lymph nodes per CT criteria or PET avid lymph nodes&#xD;
&#xD;
          9. No lymphadenopathy outside the surgical field (i.e. celiac or para-aortic adenopathy)&#xD;
&#xD;
         10. Adequate cardiopulmonary reserves to tolerate surgery&#xD;
&#xD;
         11. Karnofsky performance status &gt; 70&#xD;
&#xD;
         12. Age &gt;18&#xD;
&#xD;
         13. Adequate bone marrow function defined as follows:&#xD;
&#xD;
         14. Absolute neutrophil count (ANC) &gt; 1800 cells/mm3&#xD;
&#xD;
         15. Platelets â‰¥ 100,000 cells/mm3&#xD;
&#xD;
         16. Hemoglobin &gt; 8.0 g/dl (Note: The use of transfusion or other intervention to achieve&#xD;
             Hgb &gt; 8 g/dl is acceptable.)&#xD;
&#xD;
         17. Pregnancy test must be negative for women of childbearing potential within 7 days&#xD;
             prior to study entry&#xD;
&#xD;
         18. Patient must sign study specific informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior surgical resection of any pancreatic malignancy&#xD;
&#xD;
          2. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free&#xD;
             for a minimum of 3 years&#xD;
&#xD;
          3. Any prior chemotherapy or radiation for treatment of the patient's pancreatic tumor.&#xD;
&#xD;
          4. Prior radiotherapy to the region of the study cancer that would result in overlap of&#xD;
             radiation therapy fields&#xD;
&#xD;
          5. Severe, active comorbidity, defined as follows:&#xD;
&#xD;
               1. Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the last 12 months&#xD;
&#xD;
               2. Transmural myocardial infarction within the last 6 months&#xD;
&#xD;
               3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration&#xD;
&#xD;
               4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy within 30 days prior to&#xD;
                  registration.&#xD;
&#xD;
          6. Severe, uncorrectable hepatic insufficiency and/or coagulation defects due to liver&#xD;
             failure&#xD;
&#xD;
          7. Any evidence of distant metastases (M1)&#xD;
&#xD;
          8. Pregnancy or women of childbearing potential and men who are sexually active and not&#xD;
             willing/able to use medically acceptable forms of contraception; this exclusion is&#xD;
             necessary because the treatment involved in this study may be significantly&#xD;
             teratogenic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan W Katz, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Alan Katz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

